Literature DB >> 21785551

The Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 Infection.

Jason J Schafer, Saranyu Ravi, Evelyn V Rowland, Germin Shenoda, Nicholas Leon.   

Abstract

Entities:  

Year:  2011        PMID： 21785551      PMCID： PMC3138374     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  62 in total

1.  Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.

Authors:  Monika Schöller-Gyüre; Thomas N Kakuda; Goedele De Smedt; Brian Woodfall; Cindy Berckmans; Monika Peeters; Richard M W Hoetelmans
Journal:  Clin Ther       Date:  2010-02       Impact factor: 3.393

2.  Antiretroviral therapies in women after single-dose nevirapine exposure.

Authors:  Shahin Lockman; Michael D Hughes; James McIntyre; Yu Zheng; Tsungai Chipato; Francesca Conradie; Fred Sawe; Aida Asmelash; Mina C Hosseinipour; Lerato Mohapi; Elizabeth Stringer; Rosie Mngqibisa; Abraham Siika; Diana Atwine; James Hakim; Douglas Shaffer; Cecilia Kanyama; Kara Wools-Kaloustian; Robert A Salata; Evelyn Hogg; Beverly Alston-Smith; Ann Walawander; Eva Purcelle-Smith; Susan Eshleman; James Rooney; Sibtain Rahim; John W Mellors; Robert T Schooley; Judith S Currier
Journal:  N Engl J Med       Date:  2010-10-14       Impact factor: 91.245

3.  Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers.

Authors:  Bharat Damle; Robert LaBadie; Penelope Crownover; Paul Glue
Journal:  Br J Clin Pharmacol       Date:  2008-02-20       Impact factor: 4.335

4.  Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants.

Authors:  Kalyan Das; Arthur D Clark; Paul J Lewi; Jan Heeres; Marc R De Jonge; Lucien M H Koymans; H Maarten Vinkers; Frederik Daeyaert; Donald W Ludovici; Michael J Kukla; Bart De Corte; Robert W Kavash; Chih Y Ho; Hong Ye; Mark A Lichtenstein; Koen Andries; Rudi Pauwels; Marie-Pierre De Béthune; Paul L Boyer; Patrick Clark; Stephen H Hughes; Paul A J Janssen; Eddy Arnold
Journal:  J Med Chem       Date:  2004-05-06       Impact factor: 7.446

5.  Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.

Authors:  Edwin Dejesus; Benjamin Young; Javier O Morales-Ramirez; Louis Sloan; Douglas J Ward; John F Flaherty; Ramin Ebrahimi; Jen-Fue Maa; Karen Reilly; Janet Ecker; Damian McColl; Daniel Seekins; Awny Farajallah
Journal:  J Acquir Immune Defic Syndr       Date:  2009-06-01       Impact factor: 3.731

6.  Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.

Authors:  Ferdinand W N M Wit; Anouk M Kesselring; Luuk Gras; Clemens Richter; Marchina E van der Ende; Kees Brinkman; Joep M A Lange; Frank de Wolf; Peter Reiss
Journal:  Clin Infect Dis       Date:  2008-03-15       Impact factor: 9.079

7.  Persistence of nevirapine in breast milk and plasma of mothers and their children after single-dose administration.

Authors:  Andrea Kunz; Monika Frank; Kizito Mugenyi; Rose Kabasinguzi; Astrid Weidenhammer; Michael Kurowski; Charlotte Kloft; Gundel Harms
Journal:  J Antimicrob Chemother       Date:  2008-10-30       Impact factor: 5.790

8.  Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.

Authors:  Jeffrey P Nadler; Daniel S Berger; Gary Blick; Paul J Cimoch; Calvin J Cohen; Richard N Greenberg; Charles B Hicks; Richard M W Hoetelmans; Kathy J Iveson; Dushyantha S Jayaweera; Anthony M Mills; Monika P Peeters; Peter J Ruane; Peter Shalit; Shannon R Schrader; Stephen M Smith; Corklin R Steinhart; Melanie Thompson; Johan H Vingerhoets; Ellen Voorspoels; Douglas Ward; Brian Woodfall
Journal:  AIDS       Date:  2007-03-30       Impact factor: 4.177

9.  Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients.

Authors:  Alberto Matteelli; Mario Regazzi; Paola Villani; Giuseppina De Iaco; Maria Cusato; Anna Cristina C Carvalho; Silvio Caligaris; Lina Tomasoni; Maria Manfrin; Susanna Capone; Giampiero Carosi
Journal:  Curr HIV Res       Date:  2007-05       Impact factor: 1.581

10.  Pharmacokinetic study of the interaction between itraconazole and nevirapine.

Authors:  Sutep Jaruratanasirikul; Somchai Sriwiriyajan
Journal:  Eur J Clin Pharmacol       Date:  2007-03-07       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.